Literature DB >> 23916696

Dimethyl fumarate regulates histone deacetylase expression in astrocytes.

Sergey Kalinin1, Paul E Polak, Shao Xia Lin, David Braun, Marina Guizzetti, Xiaolu Zhang, Israel Rubinstein, Douglas L Feinstein.   

Abstract

We previously showed that dimethyl fumarate (DMF) reduces inflammatory activation in astrocytes, involving activation of transcription factor Nrf2. However, the pathways causing Nrf2 activation were not examined. We now show that DMF modifies expression of histone deacetylases (HDACs) in primary rat astrocytes. After 4h incubation, levels of HDAC1, 2, and 4 mRNAs were increased by DMF; however, after 24h, levels returned to or were below control values. At that time, HDAC protein levels and overall activity were also reduced by DMF. Stimulation of astrocytes with pro-inflammatory cytokines significantly increased HDAC mRNA levels after 24h, although protein levels were not increased at that time point. In the presence of cytokines, DMF reduced HDAC mRNAs, proteins, and activity. Proteomic analysis of DMF-treated astrocytes identified 8 proteins in which lysine acetylation was increased by DMF, including histones H2a.1 and H3.3. A role for HDACs in mediating DMF actions is suggested by findings that the selective HDAC inhibitor SAHA increased nuclear Nrf2:DNA binding activity, reduced inflammatory activation of astrocytes which was reversed by a selective inhibitor of the Nrf2 target gene heme-oxygenase 1. These data show that DMF regulates astrocyte HDAC expression, which could contribute to Nrf2 activation, suppression of inflammatory responses and cause long-lasting changes in gene expression. Published by Elsevier B.V.

Entities:  

Keywords:  Astrocyte; Histone deacetylase; Multiple sclerosis; Nrf2

Mesh:

Substances:

Year:  2013        PMID: 23916696     DOI: 10.1016/j.jneuroim.2013.07.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

Review 1.  Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.

Authors:  Sudhir Kumar Yadav; Devika Soin; Kouichi Ito; Suhayl Dhib-Jalbut
Journal:  J Mol Med (Berl)       Date:  2019-02-28       Impact factor: 4.599

Review 2.  Complex neuroprotective and neurotoxic effects of histone deacetylases.

Authors:  Elizabeth A Thomas; Santosh R D'Mello
Journal:  J Neurochem       Date:  2018-04-06       Impact factor: 5.372

3.  The Long-Lasting Rodenticide Brodifacoum Induces Neuropathology in Adult Male Rats.

Authors:  Sergey Kalinin; Natalia Marangoni; Katarzyna Kowal; Arunangsu Dey; Kinga Lis; Sergey Brodsky; Richard van Breemen; Zane Hauck; Richard Ripper; Israel Rubinstein; Guy Weinberg; Douglas L Feinstein
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

Review 4.  Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration.

Authors:  Matthew Neal; Jason R Richardson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-11-04       Impact factor: 5.187

5.  Prodrugs Bioactivated to Quinones Target NF-κB and Multiple Protein Networks: Identification of the Quinonome.

Authors:  Emily N Pierce; Sujeewa C Piyankarage; Tareisha Dunlap; Vladislav Litosh; Marton I Siklos; Yue-Ting Wang; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2016-06-13       Impact factor: 3.739

6.  Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.

Authors:  Elizabeth A Thomas
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-26

Review 7.  Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Authors:  Jacqueline Ann Nicholas; Aaron Lee Boster; Jaime Imitola; Colleen O'Connell; Michael Karl Racke
Journal:  Drug Des Devel Ther       Date:  2014-07-07       Impact factor: 4.162

8.  Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia.

Authors:  Sunil Sahdeo; Brian D Scott; Marissa Z McMackin; Mittal Jasoliya; Brandon Brown; Heike Wulff; Susan L Perlman; Mark A Pook; Gino A Cortopassi
Journal:  Hum Mol Genet       Date:  2014-08-11       Impact factor: 6.150

Review 9.  Epigenetic Drugs for Multiple Sclerosis.

Authors:  Jacob Peedicayil
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 10.  Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.